Against which human papillomavirus types shall we vaccinate and screen? The international perspective
about
Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytesProphylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursorsProphylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursorsProphylactic human papillomavirus vaccinesEuropean Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary documentHuman papillomavirus and HPV vaccines: a reviewThe viral etiology of AIDS-associated malignanciesPrevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, IndiaHuman papillomavirus related cervical cancer and anticipated vaccination challenges in EthiopiaAre the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPVAutophagy knocked down by high-risk HPV infection and uterine cervical carcinogenesisHuman Papillomaviruses; Epithelial Tropisms, and the Development of NeoplasiaCurrent status of human papillomavirus vaccinesA Content Analysis of Arabic and English Newspapers before, during, and after the Human Papillomavirus Vaccination Campaign in the United Arab Emirates.Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world?The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next?Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccinesAutomated biochemical, morphological, and organizational assessment of precancerous changes from endogenous two-photon fluorescence imagesDurable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopesCapsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approachA pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2Capsomer vaccines protect mice from vaginal challenge with human papillomavirusType-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic review and meta-analysisDistinctive distribution of HPV genotypes in cervical cancers in multi-ethnic Suriname: implications for prevention and vaccination.Human papillomavirus 16 E5 induces bi-nucleated cell formation by cell-cell fusion.Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women.Analysis of liquid bead microarray antibody assay data for epidemiologic studies of pathogen-cancer associations.More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population.Human Papillomavirus type distribution in invasive cervical cancer in UgandaEstimating progression rates for human papillomavirus infection from epidemiological data.Genotype distribution of human papillomavirus (HPV) and co-infections in cervical cytologic specimens from two outpatient gynecological clinics in a region of southeast SpainA cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.HPV prevalence in Colombian women with cervical cancer: implications for vaccination in a developing countrySafety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial.Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in non-vaccinated women.Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from ItalyHuman Papilloma Virus (HPV) in head and neck region: review of literature.Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe.
P2860
Q21143868-C631D010-9798-4888-B45A-AEF80E0E4827Q24202048-64F38CDE-D741-494C-A655-A6BEAFDD6FCFQ24235373-FD2A8165-E61B-41B3-AC1C-BF7917B15170Q24545449-B3CE9F51-31A8-4EB4-AAB9-269366B7F32DQ24644710-F0C8C0D0-6712-4C55-A80B-D7770EFDFA13Q24657891-AE7AADA4-9170-4C73-B7D4-5FD2304CD25DQ24685892-CA8D02DA-4FEE-4AF4-9CDA-2BFE1160E7A9Q25257293-DAC43BEA-8636-4AFE-B983-DA937A59DC14Q26752696-FD0DB269-B0C3-4FE4-922C-6BE0A3FFB8E9Q26783973-DE157577-AA29-4C38-B316-30C186832EF2Q26784314-A82895E0-DFD3-4AA1-B26D-D22CEA412301Q26801768-A2A83983-483E-40E9-B605-8519E246434AQ26991640-AB82492F-B30C-4329-8871-89ED5E9AE97CQ27303679-C1B985D0-7C9A-485E-8990-47270283F26CQ27692056-1790363A-2DDB-40D8-A106-2B05CECA39C9Q28074014-0561EC0A-2E99-4197-A747-BE7572D8479BQ28246307-53CD5500-1820-405F-B0C5-5833E43AC178Q28477042-F336931C-1E50-4D79-AE20-63C9CBEBDD50Q28603888-2C4D68BB-180B-4D6D-AB0D-393F43755B82Q28607775-D550859B-EDAB-44C7-87A0-68DCF5DE84D4Q28741364-4AF0598F-A244-4228-A329-30087864F956Q28743261-F4C6458F-41F0-46FA-9820-8E88B0D81DDEQ28744257-4C87895E-5D89-434A-B631-E0C0A18ED205Q29353543-ADA0B583-0E71-49AD-8A2D-A02C242904CFQ30486597-FCB14CFE-FF4E-489A-B305-5BD3CE23A82AQ30573204-A9FD1898-6DA9-4DD1-9CA4-B1999D57DBD9Q30712681-17C4DB6D-AB6C-433C-B2EA-B6AEFAD4AEB7Q30970993-1CA1EB2D-B053-4A94-B97D-8F278141ACE3Q33246180-626AA325-CE89-4745-A665-DE8F3A6E1ACFQ33346465-81AA3E72-FC44-409E-B09F-CC5C1AA48586Q33467330-3906CCE6-AEF8-47FF-A2FC-7CD6E47E1514Q33491832-1967EA80-6BAE-493A-BB9D-DAD5B6EFF8FEQ33514126-74665053-FC32-4C1F-A4D5-9254655A72DAQ33568522-5AB62790-3782-4ACC-B337-52622D1FA735Q33579684-70562673-873E-484A-84BE-F81FBA5DBB0CQ33591582-0B248698-F8E5-430E-8067-6DFBB2B134DFQ33592432-A251CA47-F292-42BB-9626-638A63807466Q33595321-0A130BCA-761E-4CC5-9D72-8F56BA65092DQ33626377-D33C0186-1F48-4081-920C-E63BCC181542Q33638491-A84E9A5C-280D-4E20-B152-7AB601AEA37A
P2860
Against which human papillomavirus types shall we vaccinate and screen? The international perspective
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Against which human papillomav ...... The international perspective
@ast
Against which human papillomav ...... The international perspective
@en
Against which human papillomav ...... The international perspective
@nl
type
label
Against which human papillomav ...... The international perspective
@ast
Against which human papillomav ...... The international perspective
@en
Against which human papillomav ...... The international perspective
@nl
prefLabel
Against which human papillomav ...... The international perspective
@ast
Against which human papillomav ...... The international perspective
@en
Against which human papillomav ...... The international perspective
@nl
P2093
P2860
P50
P3181
P356
P1476
Against which human papillomav ...... The international perspective
@en
P2093
Chris J L M Meijer
Doudja Hammouda
F Xavier Bosch
Keerti V Shah
Nubia Muñoz
Silvia de Sanjose
P2860
P304
P3181
P356
10.1002/IJC.20244
P407
P577
2004-08-20T00:00:00Z